When the world shut down, Roche went all-in and carried on its research programs

It was no easy decision to keep clinical trials going last spring, when the Covid-19 pandemic escalated, but Roche quickly decided that it would keep as much research going as it could, says research executive. This is now paying off.

Roche SVP, Global Head Oncology, Pharma Research and Early Development Dominik Ruettinger. | Photo: Roche / PR

Even though pharmaceutical companies, overall, have not been hit as hard by the Covid-19 pandemic as most other industries, pharmaceutical and biotech companies have been especially challenged in one particular area, which is that of clinical research.

Once the pandemic really started having an impact, many companies were at a loss for what to do. One of them was Roche, according to Dominik Ruettinger, the pharmaceutical firm's senior vice president and global head of Oncology, Pharma Research and Early Development (pRed).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs